499 assets in Hepatocellular Carcinoma

Therapeutic assets addressing Hepatocellular Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sufentanyl Hepatocellular Carcinoma	The First Affiliated Hospital with Nanjing Medical University	P4	B (58)
Tiragolumab Hepatocellular Carcinoma	Hoffmann-La Roche	P3	B (58)
Trametinib Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P2	B (58)
Wgi-0301 Hepatocellular Carcinoma	Zhejiang Haichang Biotech Co., Ltd.	P2	B (58)
Yttrium (90 Y) Hepatocellular Carcinoma	Second Affiliated Hospital of Guangzhou Medical University	P3	B (58)
188re-sss lipiodol Hepatocellular Carcinoma	Center Eugene Marquis	P2	B (57)
Acetylcysteine Hepatocellular Carcinoma	Institute of Liver and Biliary Sciences, India	P2	B (57)
Bat-1706 (Biosimilar Of Bevacizumab) Hepatocellular Carcinoma	BeiGene	P2	B (57)
ga-68 dolacga Hepatocellular Carcinoma	National Atomic Research Institute, Taiwan	P2	B (57)
Ociperlimab Hepatocellular Carcinoma	BeiGene	P2	B (57)
Oxycodone Hepatocellular Carcinoma	The First Affiliated Hospital with Nanjing Medical University	P4	B (57)
(+)-Vincristine Hepatocellular Carcinoma	University of Birmingham	P3	B (57)
Atorvastatin Hepatocellular Carcinoma	Chiayi Christian Hospital	P4	B (56)
Babaodan Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P4	B (56)
FCH Hepatocellular Carcinoma	Queen's Medical Center	P3	B (56)
Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) Hepatocellular Carcinoma	Fudan University	P3	B (56)
Jnj-54135419 Hepatocellular Carcinoma	The Second Affiliated Hospital of Chongqing Medical University	P4	B (56)
Metformin Hepatocellular Carcinoma	Dan Zandberg	P3	B (56)
Nanocrystalline Megestrol Acetate Suspension Hepatocellular Carcinoma	Nanfang Hospital, Southern Medical University	P3	B (56)
Prednisone Hepatocellular Carcinoma	Pfizer	P3	B (56)
Rilvegostomig Hepatocellular Carcinoma	AstraZeneca	P3	B (56)
Sevoflurane Hepatocellular Carcinoma	Kaohsiung Medical University Chung-Ho Memorial Hospital	P4	B (56)
Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester Hepatocellular Carcinoma	Qing XIe	P4	B (56)
Tpst-1120 Hepatocellular Carcinoma	Tempest Therapeutics	P3	B (56)
Envafolimab Hepatocellular Carcinoma	Anhui Provincial Hospital	P2	CCC (55)
Guadecitabine Hepatocellular Carcinoma	University of Southern California	P2	CCC (55)
Inkt Cells Hepatocellular Carcinoma	Beijing YouAn Hospital	P2	CCC (55)
Mtl-Cebpa Hepatocellular Carcinoma	Mina Alpha Limited	P2	CCC (55)
Palbociclib Hepatocellular Carcinoma	Henan Cancer Hospital	P2	CCC (55)
Pracytarabine Hepatocellular Carcinoma	Xi'an Xintong Pharmaceutical Research Co.,Ltd.	P2/3	CCC (55)
Tti 101 Hepatocellular Carcinoma	Tvardi Therapeutics, Incorporated	P1/2	CCC (55)
vrt106 Hepatocellular Carcinoma	Guangzhou Virotech Pharmaceutical Co., Ltd.	P2/3	CCC (55)
Abiraterone Hepatocellular Carcinoma	Exelixis	P3	CCC (54)
Budigalimab Hepatocellular Carcinoma	AbbVie	P2/3	CCC (54)
pm8002 Hepatocellular Carcinoma	Biotheus Inc.	P2	CCC (54)
Recombinant Human Il12/15-Pdl1B Oncolytic Hsv-1 ) Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)
Recombinant Interleukin-12 Hepatocellular Carcinoma	CNBG-Virogin Biotech (Shanghai) Ltd.	P1/2	CCC (54)
Tenofovir Hepatocellular Carcinoma	Zhongshan Hospital (Xiamen), Fudan University	P3	CCC (54)
Zoledronate Hepatocellular Carcinoma	Sun Yat-sen University	P3	CCC (54)
Absk-011 Hepatocellular Carcinoma	Abbisko Therapeutics Co, Ltd	P2	CCC (53)
Amino Acids, Branched-Chain Hepatocellular Carcinoma	Fudan University	P2	CCC (53)
Amivantamab-Vmjw Hepatocellular Carcinoma	Janssen Research & Development, LLC	P2	CCC (53)
Anti-Egfr Antibody-Drug Conjugate Mrg003 Hepatocellular Carcinoma	Fudan University	P2	CCC (53)
Bevacizumab Biosimilar Ql 1101 Hepatocellular Carcinoma	Sun Yat-sen University	P2	CCC (53)
Binimetinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Capivasertib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Cobimetinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Dalpiciclib Isetionate Hepatocellular Carcinoma	Sun Yat-sen University	P2	CCC (53)
Dasatinib Hepatocellular Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)

Showing 101 to 150 of 499 assets

PreviousPage 3 of 10Next